PARP1 and cancer: Nearly two decades ago, the discovery of the synthetic lethality interaction between two crucial DNA damage repair proteins, PARP1 and BRCA1/2 [1,2], instigated cancer therapy with PARP inhibitors (PARPi), targeting tumors with high genomic instability (Figure 1A).